{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017917","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.712043+00:00","generated_at":"2026-06-21T18:04:55.772182+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Path Q3 net loss widens to $3.5M; begins Phase 1/1b for BP1002 in AML","bullets":["Net loss $3.5M ($0.49/share) vs $2.1M ($0.29/share) in Q3 2021.","R&D expense doubled to $2.4M on manufacturing costs and BP1001-A trial startup.","Cash $13.7M at Sep 30, 2022, down from $23.8M at Dec 31, 2021; YTD ops burn $10.1M.","First patient dosed in Phase 1/1b study of BP1002 for refractory/relapsed AML.","Closed $2.0M registered direct offering of 800k shares at $2.50 each, with warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017917","json":"https://secwatch.observer/filing/0001558370-22-017917.json","markdown":"https://secwatch.observer/filing/0001558370-22-017917.md","text":"https://secwatch.observer/filing/0001558370-22-017917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837022017917/0001558370-22-017917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837022017917/bpth-20221115x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:04:55.772182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1204bd7347aca2fb331a474ccecc6e81e42db53c","claim":"BIO-PATH HOLDINGS, INC. reported three months ended September 30, 2022 results: net income Net loss of $3.5 million, EPS $0.49 per share.","evidence_excerpt":"The Company reported a net loss of $3.5 million, or $0.49 per share, for the three months ended September 30, 2022, compared to a net loss of $2.1 million, or $0.29 per share, for the three months ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000155837022017917/0001558370-22-017917-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Net income","value":"Net loss of $3.5 million"},{"label":"EPS","value":"$0.49 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}